Is individualized medicine more cost-effective? A systematic review (Q38191496)

30 August 2017

1 reference

title

Is individualized medicine more cost-effective? A systematic review (English)

1 reference

30 August 2017

1 reference

Maximilian H M Hatz

1

1 reference

30 August 2017

Katharina Schremser

series ordinal

2

1 reference

30 August 2017

Wolf H Rogowski

series ordinal

3

1 reference

30 August 2017

publication date

1 May 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

32

1 reference

30 August 2017

issue

5

1 reference

30 August 2017

page(s)

443-455

1 reference

Payer perspectives on pharmacogenomics testing and drug development.

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Personalized oncology: recent advances and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

The role of cost-effectiveness analysis in the era of pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Points to consider in assessing and appraising predictive genetic tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Economic analyses of human genetics services: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

A systematic review of cost-effectiveness analyses of pharmacogenomic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Cost effectiveness of pharmacogenomics: a critical and systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Genetic screening by DNA technology: a systematic review of health economic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Effectiveness and cost-effectiveness of prognostic markers in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Cost-effectiveness of testing for breast cancer susceptibility genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Within a smoking-cessation program, what impact does genetic information on lung cancer need to have to demonstrate cost-effectiveness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Gene expression profiling and breast cancer care: what are the potential benefits and policy implications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Cost-effectiveness of genetic testing in family members of patients with long-QT syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Testing women with endometrial cancer to detect Lynch syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Cost-utility analysis of genetic screening in families of patients with germline MUTYH mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Endogenous cost-effectiveness analysis and health care technology adoption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Pharmacogenomics and public health

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Pharmacogenomics, evidence, and the role of payers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Economic opportunities and challenges for pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0143-0

A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer

21 January 2018

1 reference

12 December 2020

Further opportunities for cost reduction of medical care

1 reference

12 December 2020

Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis.

1 reference

12 December 2020

Current impact of gene technology on healthcare. A map of economic assessments

1 reference

12 December 2020

A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory

1 reference

12 December 2020

Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer.

1 reference

12 December 2020

Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer

1 reference

12 December 2020

The cost-effectiveness of interleukin-1 genetic testing for periodontal disease

1 reference

12 December 2020

Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance

1 reference

12 December 2020

Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa

1 reference

12 December 2020

Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer.

1 reference

12 December 2020

Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer

1 reference

12 December 2020

Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2

1 reference

12 December 2020

Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization

1 reference

12 December 2020

Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.

1 reference

12 December 2020

10.1007/S40273-014-0143-0

Identifiers

DOI

1 reference

30 August 2017

1 reference